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the limited availability of databases reporting the same information in Italy, the
objectives of this study were to assess the applicability of the Belgian analysis, and
to estimate cost differences between ESAs in Italy.METHODS: To adapt the Belgian
data for the Italian setting, costs were replaced with Italian-specific costs, and
discrepancies in epidemiology and treatment patterns were examined. Adjusting
for country discrepancies, costs were analyzed using a mixed-effects model strat-
ifying for propensity score quintiles as in Spaepen et al. Sources included Eurostat,
national cancer registries, IMS sales data, treatment and reimbursement guide-
lines, and reimbursement public tariffs. RESULTS: The Italian and Belgian popula-
tions were similar in terms of age, gender, ESA use and blood transfusions. The
Belgian dataset was adjusted to reflect the incidence of haematological, lung, fe-
male breast and female genital cancers. No major differences between countries
were found regarding the use of ESAs or blood transfusions. In Italy, total costs
(meanSE) were €10,546873 for DARB versus €14,063745 and €13,274910 for
EPO-A (p0.0001) and EPO-B (p0.0008), respectively. Anaemia-related costs were
€3,144211 for DARB versus €5,049119 and €3,656230 for EPO-A (p0.0001) and
EPO-B (p0.0935). ESA costs were €2,475187 for DARB versus €4,241115 and
€3,115203 for EPO-A (p0.0001) and EPO-B (p0.0139). CONCLUSIONS: Total and
anaemia-related costs were lowest in patients receiving DARB compared with
EPO-A and EPO-B in Italy. These findings are consistent with those from the Belgian
analysis. Adapting Belgian data to Italy is feasible when accounting for patient and
treatment characteristics and costs.
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OBJECTIVES: Capecitabine (C) is approved in Brazil to treat colorectal cancer CRC,
and can replace the combination of 5fluorouracl (5FU) and folinic acid (FA) in many
chemotherapy (CHEMO) combination. There are restrictions to their use in the
private sector in Brazil, as oral (PO) CHEMO is not covered by health insurance plans
(HI). For many patients and physicians, a PO option is preferred over the intrave-
nous (IV) . Our aim was to study the budgetary impact linked to the use of C for the
treatment of CRC in HI. METHODS: We searched Evidencias Database for CRC
patients eligible for the use of C, in the year of 2008. This database has information
from over 2 million of users of 14 HI. We calculated the costs of the IV chemo
actually used (mainly combinations of 5FU-FA with oxaliplatin and irinotecan). We
calculated the costs of the drug used and, when appropriate, the infusion pump to
deliver 5FU by continuous infusion. Then, based on the real data of each individual
patient, we calculated the costs if C replaced 5FU-FA in the CHEMO. We assumed
both treatments would have the same efficacy, as reported in the literature.
RESULTS: We found 315 records of CRC patients that used IV Chemo and could
replace it by C. These patients received 2706 cycles of treatment and had an actual
total cost of US$7,237,000 (85% of them refers to the CHEMO drugs only). If C replace
5FU-FA in the IV CHEMO, the total cost would drop 9.5%, to US$6,804,000, mainly
due to the exclusion of the need of an infusion pump. CONCLUSIONS: The use of C
to treat CRC is linked to a smaller cost than the IV alternative in the private health
plans in Brazil.
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OBJECTIVES: Lung cancer is one of the most common cancers in the world. Stan-
dard curative therapy includes surgical resection of the primary tumour. Under-
standing how to combine best clinical outcomes for the most efficient use of re-
sources is important. We undertook a systematic review of the costs related to
managing early stage lung cancer to summarize the body of literature from the
global community.METHODS:An electronic literature search of EMBASE, MEDLINE
and HEALTHSTAR was performed (January 2000-August 1, 2010). The search terms
“Lung Cancer” and “Costs and Cost Analysis” or “Economics” were used. Two re-
viewers independently evaluated articles and consensus was achieved for all dis-
cordant evaluations. Data were abstracted using a standardized abstraction form.
Costs are reported in 2010 Canadian dollars. RESULTS: The literature search iden-
tified 3654 abstracts; 25 articles were included and the research spanned 13 coun-
tries. The majority (15/25) of the studies performed cost identification studies; the
remainder included 9 cost-effectiveness and 1 cost-utility analyses. Prospective
research was performed in only one study. Just over 50% (13/25) of the studies
reported a perspective, while 14/25 specified a time horizon for cost and health
outcome collection. Overall costs for treating early NSCLC ranged from $24,040 (no
recurrence) to $97,774 (persistent recurrence). The mean costs per patient for sur-
gery ranged from $88 (lobectomy chest drain equipment) to $92,967 (thoracotomy
lobectomy). CONCLUSIONS: The literature varies in adherence to optimal assess-
ment methodology, and room for improvement is evident. Costs vary by treatment
modality, yet few comparisons of available options exist for this population. Fur-
ther comparisons of population-based clinical and economic outcomes are neces-
sary in order to understand the burden of early lung cancer. This systematic review
of the costs of early lung cancer may help to inform the methodologies and costs for
future cost-effectiveness evaluations.
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OBJECTIVES: To compare the costs associated to second-line chemotherapies for
adNSCLC in France. Three therapies, docetaxel, pemetrexed and erlotinib are cur-
rently marketed in France for second-line management of advanced non-small-
cell lung cancer (adNSCLC). Published studies showed no statistically differences
between these treatments in term of efficacy (median progression-free survival or
survival), but there are few data on the costs of these therapies. METHODS: A
cost-minimization analysis was based on an indirect comparison of the results of
two prospective randomized French clinical trials (GFPC05-06 and CYTAR) in sec-
ond-line setting. Costs were estimated in the perspective of the French National
Sickness Fund and included direct treatments costs (excluding transports) and
in-patients costs both for treatment administration and potential adverse events.
All costs were estimated on a 100 days period. RESULTS: Studied population in-
cluded 145 patients treated with erlotinib, 75 patients treated with docetaxel and 75
with pemetrexed. Characteristics of patients were assumed to be similar. Overall,
the median direct costs of the second line chemotherapies/100 management days
were: 9,009€ (IQR: 8,403-12,291) for docetaxel, 14,229€ (IQR: 12,718-20,099) for pem-
etrexed and 7,134€ (IQR: 6,752-8669) for erlotinib. Two by two, total costs differ-
ences between compared chemotherapies were all statistically significant
(p0.001). The cost breakdowns among drug costs, in-patient stays for drug deliv-
ery, tests and supportive care and adverse events were respectively 85%, 0%, 0%,
15% (erlotinib), 73%, 6%, 6%, 15% (pemetrexed), and 59%, 20%, 7%, 14% (docetaxel).
CONCLUSIONS: Costs of second-line therapies for adNSCLC appeared to be slightly
lower using erlotinib as compared with docetaxel and pemetrexed due to lower
administration costs. However, this study was based only on an indirect compar-
ison and head to head trials are required to confirm such a conclusion.
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OBJECTIVES: An economic evaluation was undertaken to compare the treatment
cost of patients on darbepoetin alfa (DA) 500 mcg once every 3 weeks (Q3W) and 150
mcg weekly (QW), epoetin-alfa (EA) 40,000 IU QW, epoetin-beta (EB) 30,000 IU QW
and 3-times weekly (TIW) in the management of chemotherapy-induced anaemia
(CIA) in Greece. METHODS: : The analysis was based on a decision tree model
reflecting the local management of patients, driven primarily by their response to
therapy (measured in terms of an increase in haemoglobin concentration 2 g/Dl).
As therapies are assumed to be of similar efficacy, a cost-minimisation analysis
was undertaken considering National Health Services and patient transportation
costs. Different data on the dose and cost of drugs, and frequency of therapy and
response rates, were obtained from the published literature, expert opinions and
registries. The model was probabilistic and was used to run Monte Carlo simula-
tions to compensate for uncertainty. Results correspond to 2011 costs. RESULTS:
The mean total cost per patient treated with DA-Q3W was €2951 (95% Uncertainty
Interval (UI): €2912-2992), DA-QW €3192 (95%UI: €3075-3308), EA-QW €3781 (95%UI:
€3646-3914), EB-TIW €4908 (95%UI: €4563-5251), and EB-QW €3956 (95%UI: €3821-
4089). Cost-savings associated with DA-Q3W were: 8% relative to DA-QW; 22% to
EA-QW; 40% to EB-QW; and 25% to EB-TIW. The mean cost per response to DA-Q3W
was €3999 (95%UI: €3760-€4241); to DA-QW €4326 (95%UI: €4036-4639); to EA-QW
€5560 (95%UI: €5322-5790); to EB-TIW €7219 (95%UI: €6699-7734) and to EB-QW
€5818 (95%UI: €5575-6051). CONCLUSIONS: The present economic analysis indi-
cates that DA-Q3W and DA-QW may be associated with lower cost in comparison
with other options for the treatment of patients with CIA in Greece. Of the two
DA-based schemes, DA-Q3W appears to be associated with lower therapy cost.
Research funded by Genesis Pharma.
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OBJECTIVES:To assess the impact of brain metastasis (BrMets) on health care costs
and survival among metastatic NSCLC patients in a geographically diverse com-
mercially insured US population. METHODS: Retrospective analyses were con-
ducted using a US commercial administrative claims database linking data from a
lung cancer registry and mortality records from the Social Security Administration
Death Master File (2005-2010). Two cohorts were formed – a) with BrMets, and b)
without BrMets. Healthcare cost (hospitalization, ambulatory and pharmacy) and
resource use (hospitalization, emergency {ER} and ambulatory visits) were com-
pared using a generalized linear model (diagnosis ¡end of follow-up); a Cox pro-
portional hazard model estimated impact on survival. All models adjusted for stage
at diagnosis, pre-diagnosis comorbidity, age, and gender. RESULTS: A total of 584
metastatic NSCLC patients were included (mean 60.5 years/56.3% male): 247 (42.3%)
had claims-based evidence of BrMets and were more likely to have been diagnosed
with stage IV disease (62.8% vs. 52.2% without BrMets). Overall survival was shorter
among patients with evidence of BrMets (median 13.5 vs. 17.0 months; HR1.29,
p001); health plan enrollment duration was similar (median 11.7 months). With
similar lengths of follow-up, average health care costs following diagnosis of
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BrMets was 23% higher ($184,872 vs. $150,931; p0.010) after adjustment for other
factors. The difference was consistent across resources: 25% higher hospitalization
costs $46,871 vs. $37,504; p.082); 23% higher ambulatory costs, ($121,224 vs.
$98,276; p0.033); 23% higher retail pharmacy costs, ($13,282 vs. $10,774; p0.118).
Patients with BrMets averaged more hospitalizations (2.4 vs. 1.9; p0.005), ER visits
(2.7 vs. 2.2; p0.067), and ambulatory encounters (111 vs. 92; p0.005) from initial
NSCLC diagnosis to end of follow-up. CONCLUSIONS: Intensity of resource use and
costs were higher in metastatic NSCLC, especially in BrMets patients. Treatment
that improves disease control could reduce the intensity of cost and resource use
among NSCLC BrMets patients.
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OBJECTIVES: To assess health care resource utilization and costs among patients
with metastatic melanoma in real world practice setting. METHODS: Using a large
US medical claims database, patients were identified between 2005 and 2010 using
2melanoma diagnoses (ICD-9-CM: 172.xx, V10.82) and 2 diagnoses for metasta-
sis (ICD-9-CM: 197.xx, 198.xx). The index date was the first date of metastasis
diagnosis. Patients who had other primary malignant tumors prior to the mela-
noma diagnosis, were younger than 18 years old at the index, or had a pre-index
period of less than 6 months, were excluded from the analysis. Patients were fol-
lowed from the index date to death, disenrollment, or end of the study period (June
30, 2010), whichever occurred first. Health care utilization and health care costs
(adjusted to 2010 dollars) were examined per patient-year for office visits, outpa-
tient visits, emergency room (ER) visits and inpatient hospitalization. RESULTS: A
total of 2,546 patients with metastatic melanoma were identified. Mean ( stan-
dard deviation) age at the index was 60.6 ( 14.0) years and 36.5% were female.
Overall, 87.3% of the patients had at least one physician office visit with a mean of
24.0 visits per person-year, 64.7% had an ER visit with a mean of 12.9 visits per
person-year, 90.6% had an outpatient visit with a mean of 8.3 visits per person-
year, and 82.2% had been hospitalized with a mean of 12.4 hospitalizations per
person-year. The mean total costs per patient-year were $117,610, which was
driven mainly by inpatient costs ($60,355/patient-year) and outpatient costs
($34,540/patient-year). CONCLUSIONS: Inpatient and outpatient care are key cost
drivers in the medical management of patients with advanced melanoma.
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OBJECTIVES: Incidence of breast cancer (BC) with brain metastases (BM) is increas-
ing especially among patients with HER2-positive status. Their management is
based on diversified and expensive treatments for which costs data are scarce. We
estimated hospital costs of BCBM and their evolution within a period of two years
following BM diagnosis. METHODS: An observational retrospective multicenter
study was conducted on 207 HER2 breast cancer (BC) patients, newly diagnosed
with brain metastases (BM) as first site of relapse or secondary metastases between
January 2006 and December 2008. Data on patient profile, treatments (neurosur-
gery, radiotherapy, chemotherapy), complications leading to rehospitalisation and
hospitalisation stays were collected. Direct medical costs were estimated from the
Health Insurance perspective using Diagnosis Related Groups (DRGs) official tariffs
and expensive drugs tariffs (2007). Censored treatment cost data were analyzed
using the Bang and Tsiasis method. RESULTS: Patients were treated by radiation
therapy (91.8%), chemotherapy (84.5%) and neurosurgery (12.6%). The mean cost of
management of HER2-positive BCBMs was 18,480€/patient from 0-6 months,
16,306€ from 7-12 months, 15,844€ from 13-18 months and 15,225€ from 19-24
months. The mean cost of the first year following diagnosis was 33,847€/patient.
The proportion of costs attributed to inpatient hospitalizations stay was equal to
the one attributed to expensive drugs whatever the time period of follow-up
(17,153€/patient for hospitalizations vs 16,693€/patient for expensive drugs after
one year of follow-up). Patients with BM as first site of relapse induced more health
care resources compared to patients with secondary BM.CONCLUSIONS:The man-
agement of BCBM generates important health care resources mainly concentrated
within the first months. Health care costs decrease during the follow-up period
while the variability of costs is increasing. These results illustrate the personalized
disease management at the advanced stage of disease. Observational studies are
an interesting opportunity to estimate health care resources and associated costs
more precisely.
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OBJECTIVES: The aim of this prospective, observational, multicenter study was to
estimate the management costs of bone metastatic disease (BMD) in patients with
lung cancer. METHODS: Consecutive patients presenting BMD from lung cancer
diagnosed between May 2006 and May 2007 in 40 centers were enrolled. The natural
course of bone metastatic disease was modeled using a Markov model with 4
health states (asymptomatic patient, symptomatic patient, skeletal-related event
(SRE) and death) and a cycle length of one month, until death or a 5-year period.
Direct medical costs induced by BMD (including symptomatic or therapeutic treat-
ment and hospitalizations) were prospectively collected from the health care pro-
vider’s perspective. RESULTS:Among the 554 patients enrolled (mean age 62 years,
77% of males), 26.7% presented a SRE at diagnosis and 39% during follow-up. The
median survival time was 5.8 months, and the 1- and 2-year survival rates were
22% and 7%, respectively. The main BMD treatments were opiate therapy (78%),
biphosphonates (52%), radiotherapy (42%), and surgery (9%). The mean monthly
BMD treatment costs were 190 €, 374 €, and 4 672 € for asymptomatic patients,
symptomatic patients, and patients with SRE, respectively. The average first-year
BMD management cost was 3 999 €  4 135 (IC95%: 374-15 886), and 49.5% of this
cost was attributable to patients with SRE. CONCLUSIONS: This analysis under-
lines the burden of bone metastatic disease, and particularly of skeletal-related
event in overall treatment costs.
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OBJECTIVES: To assess an economical burden of HPV associated diseases in
Saint-Petersburg. METHODS: Total lifetime costs (direct and indirect) of HPV-asso-
ciated diseases (cervical cancer, cervical dysplasia – CIN I-III, and condylomatosis -
genital warts) in one cohort (13 years old girls in 2010; life expectancy - 74 years;
cohort amount - 16 thousands) were estimated. Epidemiologic forecast was pre-
pared based on mathematical-statistical modeling with least-square method of
regression analysis on parent observation matrix. Raw epidemiologic data on mor-
bidity and mortality were derived from official statistics. Cost of treatment was
calculated using current out-patient and hospital tariffs (in obligatory medical in-
surance program) and standards of treatment (as of 2009). Indirect costs (gross
output underproduction, disability pension, sick-pay etc.) were assessed based on
existing legislation (Federal and Saint-Petersburg’s regional). No discounting was ap-
plied in the analysis. RESULTS: Rates (per 100 000 female population) of dysplasia,
genital warts, and cervical cancer incidence, and death were 16.5, 38.7-59,7, and
13.1-17.3, and 7.1-9.6, respectively. 10 years’ growth of cervical cancer incidence
and mortality was expected to be 12-15% and 8-15% (in different age groups), re-
spectively. Total annual economic burden due to HPV diseases was 822 mln. Rub
which includes: 72 mln. Rub – treatment of cervical cancer, 637 mln. Rub – indirect
costs due to cervical cancer; 89 mln. Rub – dysplasia, 20 mln. Rub – genital warts.
Sum of total cost in one cohort was 1.1 billion Rub. CONCLUSIONS: Economic
burden of HPV-associated diseases in Saint-Petersburg in one cohort expected to be
1.1 billon Rub.
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BACKGROUND: Human papillomavirus (HPV) is the most common sexually trans-
mitted infection and is a well-established cause of anogenital cancers (responsible
for over 70% of cervical cancers). Vaccines that target the HPV strains responsible
for such cancers elicit virus-neutralising antibody responses, thus preventing the
initial infection and some re-infections associated with the same HPV types. Re-
search also suggests that HPV is a risk factor in cancers originating in the upper
aero-digestive tract, known as head and neck (HN) cancers. OBJECTIVES: To es-
timate the prevalence, incidence and associated costs of HPV-related anogenital
and HN cancers in England. METHODS: The Hospital Episode Statistics (HES)
database was used to estimate the prevalence and incidence of anogenital and
head and neck cancers in England from 2002 to 2011. An in-house epidemiologic
study and published sources were used to estimate the proportions of these can-
cers attributable to HPV . Cost estimates using Healthcare Resource Groups (HRGs)
in combination with the most recent UK National Tariff will be applied to the data.
Estimates for costs outside the scope of the National Tariff (such as rehabilitation
costs which, for example, are a key component of HN cancer treatment path-
ways) will be derived from expert opinion using resource use surveys. Results will
be validated by clinical experts in each cancer included in the analysis. RESULTS:
The analyses will highlight key areas of the broader burden of HPV-related cancers
and quantify the associated healthcare costs falling on the NHS in England. A
proportion of HPV-related cancers can be prevented through vaccination, as such,
the analysis aims to capture overall costs and, in turn, the potential for cost offsets
through the implementation of preventative healthcare pathways.CONCLUSIONS:
The use of HPV vaccines has the potential to reduce the incidence of a proportion of
HPV-related cancers, improving patient quality of life in a cost-effective manner.
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